Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

AML suppresses hematopoiesis by releasing exosomes that contain microRNAs targeting c-MYB.

Hornick NI, Doron B, Abdelhamed S, Huan J, Harrington CA, Shen R, Cambronne XA, Chakkaramakkil Verghese S, Kurre P.

Sci Signal. 2016 Sep 6;9(444):ra88. doi: 10.1126/scisignal.aaf2797.

PMID:
27601730
2.

Coordinate regulation of residual bone marrow function by paracrine trafficking of AML exosomes.

Huan J, Hornick NI, Goloviznina NA, Kamimae-Lanning AN, David LL, Wilmarth PA, Mori T, Chevillet JR, Narla A, Roberts CT Jr, Loriaux MM, Chang BH, Kurre P.

Leukemia. 2015 Dec;29(12):2285-95. doi: 10.1038/leu.2015.163. Epub 2015 Jun 25.

3.

Alterations in acute myeloid leukaemia bone marrow stromal cell exosome content coincide with gains in tyrosine kinase inhibitor resistance.

Viola S, Traer E, Huan J, Hornick NI, Tyner JW, Agarwal A, Loriaux M, Johnstone B, Kurre P.

Br J Haematol. 2016 Mar;172(6):983-6. doi: 10.1111/bjh.13551. Epub 2015 Jun 11. No abstract available.

4.

Serum Exosome MicroRNA as a Minimally-Invasive Early Biomarker of AML.

Hornick NI, Huan J, Doron B, Goloviznina NA, Lapidus J, Chang BH, Kurre P.

Sci Rep. 2015 Jun 12;5:11295. doi: 10.1038/srep11295.

5.

RNA trafficking by acute myelogenous leukemia exosomes.

Huan J, Hornick NI, Shurtleff MJ, Skinner AM, Goloviznina NA, Roberts CT Jr, Kurre P.

Cancer Res. 2013 Jan 15;73(2):918-29. doi: 10.1158/0008-5472.CAN-12-2184. Epub 2012 Nov 13.

Supplemental Content

Loading ...
Support Center